Anthera'a Varespladib Fails: Biomarkers, Outcomes Differ

Morrison, Trista
March 2012
BioWorld Today;3/13/2012, Vol. 23 Issue 49, p1
The article reports that the Phase III trial of Hayward, California-based Anthera Pharmaceuticals Inc. for its varespladib, an sPLA2 inhibitor it licensed from Eli Lilly and Co. and Shionogi & Co. Ltd., was halted for futility. It reveals that the drug reduced 15% of low-density lipoprotein cholesterol in two Phase II trials for stable acute coronary syndrome (ACS). Stephen Nicholls of Cleveland Clinic expressed his disappointment concerning the recommendation to stop the trial.


Related Articles

  • Emerging Therapies and Their Role in Comprehensive Lipid Management. Vinall, Maria // MD Conference Express;Oct2011, p6 

    The article focuses on the clinical trials which aimed to evaluate low-density lipoprotein cholesterol (LDL-C) targets and assess their significance on treatment approaches. It mentions the result of the PROVE-IT trial which support intensive statin therapy after acute coronary syndrome (ACS),...

  • Anthera reports encouraging results from Phase II cardiovascular trial.  // PharmaWatch: Biotechnology;Mar2008, Vol. 7 Issue 3, p7 

    The article discusses the preliminary results from Phase II cardiovascular trial of A-002 conducted by Anthera Pharmaceuticals Inc. The trial shows that the administration of A-002 lowered secretory phospholipase A2 (sPLA2) and low density lipoprotein cholesterol (LDL-C) levels. It confirms the...

  • Biomarkers Helpful but Not Cornucopia for Heart Drugs. Orelli, Brian // BioWorld Insight;4/9/2012, Vol. 20 Issue 15, p2 

    The article presents information on the phase III VISTA-16 trial of Anthera Pharmaceuticals Inc.'s biomarker varespladib in patients suffering from the acute coronary syndrome (ACS). It looks at the results of the phase II clinical trial of this biomarker which has shown 15 percent reduction in...

  • Intravascular ultrasound morphology of culprit lesions and clinical demographics in patients with acute coronary syndrome in relation to low-density lipoprotein cholesterol levels at onset. Takaoka, Naoko; Tsujita, Kenichi; Kaikita, Koichi; Hokimoto, Seiji; Yamanaga, Kenshi; Komura, Naohiro; Chitose, Tadasuke; Ono, Takamichi; Mizobe, Michio; Horio, Eiji; Sato, Koji; Nakayama, Naoki; Saito, Michiyo; Iwashita, Satomi; Kojima, Sunao; Tayama, Shinji; Sugiyama, Seigo; Nakamura, Sunao; Ogawa, Hisao // Heart & Vessels;Sep2014, Vol. 29 Issue 5, p584 

    Despite current standards of care aimed at achieving targets for low-density lipoprotein cholesterol (LDL-C), many patients remain at high residual risk of cardiovascular events. We sought to assess the LDL-C-dependent differences in culprit intravascular ultrasound (IVUS) morphologies and...

  • Lipids. Jones, Peter H. // Texas Heart Institute Journal;2006, Vol. 33 Issue 2, p180 

    The article discusses studies that show prevention and treatment for lipids. The reasons for focusing the lipid guidelines on low-density lipoprotein (LDL) cholesterol as the primary treatment target are mentioned. One of these reasons is that clinical data continue to show that lowering LDL...

  • Ezetimibe plus atorvastation lowers cholesterol. Madigosky, Wendy S.; Kane, Kevin Y. // Journal of Family Practice;Sep2003, Vol. 52 Issue 9, p671 

    The article presents a randomized, placebo-controlled trial of individuals with hypercholesterolemia and triclycerides to assess reduction in LDL cholesterol levels from coadministration of ezetimibe and atorvastatin. Ezetimibe is a medication which prevents intestinal absorption of cholesterol....

  • LDL cholesterol estimation in patients with the metabolic syndrome. Gazi, Irene; Tsimihodimos, Vasilis; Filippatos, Theodosios D.; Saougos, Vasilios G.; Bairaktari, Eleni T.; Tselepis, Alexandros D.; Elisaf, Moses // Lipids in Health & Disease;2006, Vol. 5, p8 

    Background: The Friedewald formula (LDL-F) for the estimation of low-density lipoprotein (LDL) cholesterol concentrations is the most often used formula in clinical trials and clinical practice. However, much concern has been raised as to whether this formula is applicable in all patient...

  • Correlation of Oxidized Low-Density Lipoprotein and C-Reactive Protein in Patients with Coronary Artery Disease. Huang, Yuli; Wu, Yanxian; Hu, Yunzhao // Cell Biochemistry & Biophysics;Mar2013, Vol. 65 Issue 2, p285 

    A letter to the editor about the correlation of oxidized low-density lipoprotein and C-reactive protein in patients with acute coronary syndrome (ACS) is presented.

  • Anthera Raises $31.5M for PEARL of Great Price.  // Bioworld Week;9/27/2010, Vol. 18 Issue 39, p4 

    The article reports that Anthera Pharmaceuticals Inc. prices its private investment in public equity financing amounting 31.5 million dollar for its Phase IIb plan for A-623 to develop an expanded clinical study or PEARL-SC in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics